217 Evaluating biomarkers of JTX-8064 (anti-LILRB2/ILT4 monoclonal antibody) in an ex vivo human tumor histoculture system to inform clinical development

• Edward Stack,
• Jeff Smith,
• Yasmin Hashambhoy-Ramsay,
• Vikki Spaulding,
• Michelle Priess,
• Kristin O’Malley,
• Monica Gostissa,
• Margaret Willer,
• Ben Umiker,
• Donald Shaffer

Affiliations

Edward Stack

Jounce Therapeutics, Cambridge, MA, USA

Jeff Smith

Jounce Therapeutics, Cambridge, MA, USA

Yasmin Hashambhoy-Ramsay

Jounce Therapeutics, Cambridge, MA, USA

Vikki Spaulding

Jounce Therapeutics, Cambridge, MA, USA

Michelle Priess

Jounce Therapeutics, Cambridge, MA, USA

Kristin O’Malley

Jounce Therapeutics, Cambridge, MA, USA

Monica Gostissa

Jounce Therapeutics, Cambridge, MA, USA

Margaret Willer

Jounce Therapeutics, Cambridge, MA, USA

Ben Umiker

Jounce Therapeutics, Cambridge, MA, USA

Donald Shaffer

Jounce Therapeutics, Cambridge, MA, USA